Emerging research are focused on Zegalogue, a dual GIP/GLP-1 receptor which appears to provide possibly superior fat reduction advantages relative to already marketed drugs like Mounjaro and Saxenda. The comparison requires a detailed look at their unique pharmacological actions, including binding s